CEL-SCI Corp. | Balance Sheet

Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
41.60
8,513.60
5,726.70
2,918.00
2,369.40
10,310
Total Accounts Receivable
74.30
81.80
87.20
394.50
218.50
118.70
Inventories
1,016.60
1,452.00
1,401.80
1,008.60
672.50
645.20
Other Current Assets
780.50
1,057.50
1,129.70
1,136.70
976.40
364.60
Total Current Assets
1,913.00
11,105.00
8,345.40
5,457.80
4,236.90
11,438.60
Net Property, Plant & Equipment
489.30
403.00
17,945.80
17,350.80
16,793.20
16,218.90
Total Investments and Advances
-
1,670.90
-
-
1,670.90
-
Intangible Assets
318.20
323.60
291.60
256.50
223.20
258.10
Other Assets
8,118.00
5,727.90
1,970.90
1,820.90
-
1,670.90
Total Assets
10,838.60
19,230.40
28,553.70
24,886.10
22,924.20
29,586.40
ST Debt & Current Portion LT Debt
1,112.30
1,130.70
1,104.10
-
994.30
Accounts Payable
1,924.50
1,160.80
5,128.70
3,091.50
8,196.30
Other Current Liabilities
508.40
861.50
472.70
920.30
1,654.00
Total Current Liabilities
3,545.10
3,153.00
6,705.50
4,011.80
10,844.60
Long-Term Debt
20.90
5,496.20
12,783.30
13,011.00
13,211.90
Other Liabilities
572.40
137.90
13,827.30
8,542.50
2,204.70
Total Liabilities
4,138.50
8,787.00
33,316.00
25,565.30
26,261.20
Common Equity (Total)
6,700.10
10,443.40
4,762.30
679.20
3,337.00
Total Shareholders' Equity
6,700.10
10,443.40
4,762.30
679.20
3,337.00
Total Equity
6,700.10
10,443.40
4,762.30
679.20
3,337.00
Liabilities & Shareholders' Equity
10,838.60
19,230.40
28,553.70
24,886.10
22,924.20

About CEL-SCI

View Profile
Address
8229 Boone Boulevard
Vienna Virginia 22182
United States
Employees -
Website http://www.cel-sci.com
Updated 07/08/2019
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients.